|
Demographics
|
|
Population
|
60,795,612
|
[18]
|
|
Male in the health plan (% of total)
|
48.5%
|
[17]
|
|
Paediatric in the health plan (% of total)
|
11.9%
|
[17]
|
|
Annual population growth
|
0.5%
|
[18]
|
|
Paediatric weight (Kg)
|
18.5
|
[21]
|
|
Adult weight (Kg)
|
70.6
|
[22]
|
|
Epidemiology
|
|
HA prevalence in male
|
12.7 per 100,000
|
[16]
|
|
Severity distribution of the disease
|
|
Mild
|
39.7%
|
[16]
|
|
Moderate
|
14.1%
|
|
Severe
|
46.2%
|
|
Patients without inhibitors
|
|
Mild
|
99.1%
|
[16]
|
|
Moderate
|
96.3%
|
|
Severe
|
81.6%
|
|
Treatment regimen among adults
|
|
On demand
|
42.8%
|
[16]
|
|
Prophylaxis
|
55.2%
|
|
Treatment regimen among paediatrics
|
|
On demand
|
0%
|
Assumption based on the opinion of clinical experts
|
|
Prophylaxis
|
100%
|
|
Costs
|
|
rFVIIIFc unit cost (€/IU)
|
0.72
|
[25]
|
|
Advate® unit cost (€/IU)
|
0.65
|
[25]
|
|
Kogenate® unit cost (€/IU)
|
0.69
|
[25]
|
|
Refacto® unit cost (€/IU)
|
0.69
|
[25]
|
|
Helixate® unit cost (€/IU)
|
0.69
|
[25]
|
|
Recombinate® unit cost (€/IU)
|
0.60
|
[25]
|
|
Plasma-derived unit cost (€/IU)
|
0.60
|
[25]
|
